Volume 53, Issue 10 pp. 2243-2247
TRANSPLANTATION AND CELLULAR ENGINEERING

Establishment of an unrelated umbilical cord blood bank qualification program: ensuring quality while meeting Food and Drug Administration vendor qualification requirements

Fran Rabe

Corresponding Author

Fran Rabe

Molecular and Cellular Therapeutics, University of Minnesota, St Paul, MN

University of Minnesota Medical Center, Fairview, Minneapolis, MN

Address correspondence to: Fran Rabe, MS, Molecular & Cellular Therapeutics, University of Minnesota, 1900 Fitch Avenue, St Paul, MN 55108; e-mail: [email protected].Search for more papers by this author
Diane Kadidlo

Diane Kadidlo

Molecular and Cellular Therapeutics, University of Minnesota, St Paul, MN

University of Minnesota Medical Center, Fairview, Minneapolis, MN

Search for more papers by this author
Lisa Van Orsow

Lisa Van Orsow

Molecular and Cellular Therapeutics, University of Minnesota, St Paul, MN

University of Minnesota Medical Center, Fairview, Minneapolis, MN

Search for more papers by this author
David McKenna

David McKenna

Molecular and Cellular Therapeutics, University of Minnesota, St Paul, MN

University of Minnesota Medical Center, Fairview, Minneapolis, MN

Search for more papers by this author
First published: 24 January 2013
Citations: 2

Abstract

Background

Qualification of a cord blood bank (CBB) is a complex process that includes evaluation of multiple aspects of donor screening and testing, processing, accreditation and approval by professional cell therapy groups, and results of received cord blood units. The University of Minnesota Medical Center Cell Therapy Laboratory has established a CBB vendor qualification process to ensure the CBB meets established regulatory and quality requirements.

Study Design and Methods

The deployed qualification of CBBs is based on retrospective and prospective review of the CBB.

Results

Forty-one CBBs were evaluated retrospectively: seven CBBs were disqualified based on failed quality control (QC) results. Eight CBBs did not meet the criteria for retrospective qualification because fewer than 3 cord blood units were received and the CBB was not accredited. As of March 2012, three US and one non-US CBBs have been qualified prospectively. One CBB withdrew from the qualification process after successful completion of the comprehensive survey and subsequent failure of the provided QC unit to pass the minimum criteria. One CBB failed the prospective qualification process based on processing methods that were revealed during the paper portion of the evaluation.

Conclusions

A CBB qualification process is necessary for a transplant center to manage the qualification of the large number of CBBs needed to support a umbilical cord blood transplantation program. A transplant center that has utilized cord blood for a number of years before implementation of a qualification process should use a retrospective qualification process along with a prospective process.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.